Figure 2
From: Suppression of endothelial cell activity by inhibition of TNFα
Certolizumab pegol inhibits TNFα-stimulated human dermal microvascular endothelial cell angiogenic chemokine secretion. ELISAs were performed to determine the concentrations of angiogenic chemokines in 24-hour TNFα (25 ng/ml)-stimulated culture supernatants. Certolizumab pegol or mouse-IgG (Ms-Ig) control were added to the cultures along with TNFα stimulation. Concentrations of representative samples show that human dermal microvascular endothelial cell (HMVEC) secreted chemokines are significantly upregulated by TNFα (*P < 0.05) and downregulated by certolizumab pegol in a concentration-dependent manner (*P < 0.05). (A) Growth-related oncogene alpha (Gro-α)/CXCL1, (B) epithelial neutrophil-activating peptide-78 (ENA-78)/CXCL5, (C) granulocyte chemotactic protein-2 (GCP-2)/CXCL6, (D) IL-8/CXCL8, (E) monocyte chemoattractant protein-1 (MCP-1)/CCL2, and (F) regulated upon activation normal T-cell expressed and secreted (RANTES)/CCL5. For each set of experiments, means of the concentration of each chemokine are given ± standard error of the mean.